Mitoxantrone

Generic Name: Mitoxantrone

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₈N_₄O_₆

CAS Number: 65271-80-9

Unique Ingredient Identifier: BZ114NVM5P

Background: An anthracenedione-derived antineoplastic agent.

Indication: For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Promyelocytic Leukemia, Hodgkin's Lymphoma, Metastatic Breast Cancer, Non-Hodgkin's Lymphoma (NHL), Progressive Relapsing Multiple Sclerosis, Relapsed Leukemia, Relapsed Lymphomas, Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), Hormone refractory, advanced Prostate cancer, Relapsed Hepatocellular carcinoma

Associated Therapies: Autologous hematopoietic stem cell transplant

Clinical Trials

A Study of Mitoxantrone Hydrochloride Liposome Infusion

Phase 1

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Mitoxantrone Hydrochloride Liposome

First Posted Date: 2016-08-05

Last Posted Date: 2016-08-22

Lead Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Target Recruit Count: 60

Registration Number: NCT02856685

Locations: 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States

Optimal Treatment Strategy Based on for Pediatric AML

Phase 2

Conditions: Pediatric Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Idarubicin
Drug: Mitoxantrone
Drug: Etoposide
Procedure: Hematopoietic stem cell transplantation

First Posted Date: 2016-07-28

Last Posted Date: 2016-07-28

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 350

Registration Number: NCT02848183

Locations: 🇰🇷
Chonnam National University Hwasun Hospital, Chonnam, Korea, Republic of
🇰🇷
St. Mary Hospital, Seoul, Korea, Republic of
🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

Phase 2

Completed

Conditions: High Grade Malignant Neoplasm
Previously Treated Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Myelodysplastic Syndrome With Excess Blasts-2
Myeloid Neoplasm
Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Chronic Myelomonocytic Leukemia-2
Myelodysplastic Syndrome

Interventions: Drug: Cladribine
Drug: Cyclosporine
Drug: Cytarabine
Biological: Filgrastim
Drug: Fludarabine Phosphate
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mitoxantrone Hydrochloride
Drug: Mycophenolate Mofetil
Other: Questionnaire Administration
Drug: Sirolimus
Radiation: Total-Body Irradiation
Drug: Melphalan Hydrochloride

First Posted Date: 2016-04-29

Last Posted Date: 2021-11-08

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT02756572

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Acute Myeloid Leukemia
de Novo Myelodysplastic Syndrome
Acute Biphenotypic Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Other: Quality-of-Life Assessment
Drug: Mitoxantrone
Drug: Sorafenib

First Posted Date: 2016-04-05

Last Posted Date: 2023-07-05

Lead Sponsor: University of Washington

Target Recruit Count: 84

Registration Number: NCT02728050

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

Phase 3

Recruiting

Conditions: Acute Myeloid Leukaemia

Interventions: Drug: Mitoxantrone
Drug: Liposomal daunorubicin
Drug: Gemtuzumab ozogamicin
Drug: Fludarabine
Drug: Cytarabine
Drug: Busulfan
Drug: Cyclophosphamide

First Posted Date: 2016-03-31

Last Posted Date: 2021-10-08

Lead Sponsor: University of Birmingham

Target Recruit Count: 700

Registration Number: NCT02724163

Locations: 🇦🇺
Monash Children's Hospital, Melbourne, Australia
🇦🇺
Women and Children's Hospital Adelaide, Adelaide, Australia
🇦🇺
Queensland Children's Hospital, Brisbane, Australia

and more 65 locations

Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Phase 3

Completed

Conditions: Acute Promyelocytic Leukemia

Interventions: Drug: Arsenic trioxide
Drug: Idarubicin
Drug: Cytarabine
Drug: Tretinoin
Drug: Mitoxantrone
Drug: Mercaptopurine
Drug: Methotrexate

First Posted Date: 2016-02-23

Last Posted Date: 2025-02-26

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 135

Registration Number: NCT02688140

Locations: 🇩🇪
OSHO study group, Multiple Locations, Germany
🇩🇪
SAL study group, Multiple Locations, Germany
🇳🇱
HOVON study group, Multiple Locations, Netherlands

and more 5 locations

A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR

Phase 1

Terminated

Conditions: Solid Tumours
CNS Tumours

Interventions: Drug: Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)

First Posted Date: 2016-02-22

Last Posted Date: 2022-02-14

Lead Sponsor: Dr David Ziegler

Target Recruit Count: 9

Registration Number: NCT02687386

Locations: 🇦🇺
The Children's Hospital at Westmead, Westmead, New South Wales, Australia
🇦🇺
Sydney Children's Hospital, Randwick, New South Wales, Australia

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Phase 1

Active, not recruiting

Conditions: Newly Diagnosed Acute Myeloid Leukemia (AML)
AML Arising After Exposure to Genotoxic Injury
Untreated AML
AML Arising From Myelodysplastic Syndrome (MDS)
AML Arising From Antecedent Hematologic Disorder (AHD)

Interventions: Drug: AG-221
Drug: AG-120
Drug: cytarabine
Drug: idarubicin
Drug: daunorubicin
Drug: mitoxantrone
Drug: etoposide

First Posted Date: 2015-12-17

Last Posted Date: 2025-04-11

Lead Sponsor: Institut de Recherches Internationales Servier

Target Recruit Count: 153

Registration Number: NCT02632708

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 14 locations

Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia

Phase 1

Terminated

Conditions: Leukemia, Acute Myelogenous

Interventions: Drug: Hydroxychloroquine
Drug: Mitoxantrone
Drug: Etoposide

First Posted Date: 2015-12-16

Last Posted Date: 2018-02-23

Lead Sponsor: Alison Sehgal, MD, MS

Target Recruit Count: 1

Registration Number: NCT02631252

Locations: 🇺🇸
University of Pittsburgh Cancer Institute - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

Phase 1

Completed

Conditions: Relapsed/Refractory Acute Myeloid Leukemia (AML)

Interventions: Drug: Crenolanib
Drug: Mitoxantrone
Drug: Cytarabine
Drug: Fludarabine
Drug: Etoposide
Drug: G-CSF
Drug: Idarubicin

First Posted Date: 2015-12-10

Last Posted Date: 2023-12-20

Lead Sponsor: Arog Pharmaceuticals, Inc.

Target Recruit Count: 16

Registration Number: NCT02626338

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Houston Methodist, Houston, Texas, United States
🇺🇸
University of Arkansas, Little Rock, Arkansas, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy